133 related articles for article (PubMed ID: 3336035)
1. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
3. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
4. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
[TBL] [Abstract][Full Text] [Related]
5. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
6. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
[TBL] [Abstract][Full Text] [Related]
7. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Gust R; Niebler K; Schönenberger H
J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
[TBL] [Abstract][Full Text] [Related]
8. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
9. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drugs: estrophilic cisplatin derivatives.
Engel J; Schönenberger H; Lux F; Hilgard P
Cancer Treat Rev; 1987 Dec; 14(3-4):275-83. PubMed ID: 2830970
[TBL] [Abstract][Full Text] [Related]
11. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
[TBL] [Abstract][Full Text] [Related]
12. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
[TBL] [Abstract][Full Text] [Related]
13. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
Gust R; Schönenberger H
Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
[TBL] [Abstract][Full Text] [Related]
14. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
Müller R; Gust R; Bernhardt G; Keller C; Schönenberger H; Seeber S; Osieka R; Eastman A; Jennerwein M
J Cancer Res Clin Oncol; 1990; 116(3):237-44. PubMed ID: 2370248
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
Gust R; Schönenberger H
Arch Pharm (Weinheim); 1994 Dec; 327(12):763-9. PubMed ID: 7872853
[TBL] [Abstract][Full Text] [Related]
16. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Spruss T; Gust R; Müller R; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines.
Otto AM; Faderl M; Schönenberger H
Cancer Res; 1991 Jun; 51(12):3217-23. PubMed ID: 2039997
[TBL] [Abstract][Full Text] [Related]
18. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
19. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
20. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]